Bisindolylmaleimide IX (Ro 31-8220) Mesylate

Bisindolylmaleimide IX (Ro 31-8220 Mesylate) is a pan-PKC inhibitor with IC50 of 5 nM, 24 nM, 14 nM, 27 nM, and 24 nM for PKC-α, PKC-βI, PKC-βII, PKC-γ, and PKC-ε, respectively, and also shows potent inhibition against MAPKAP-K1b, MSK1, GSK3β and S6K1.

Bisindolylmaleimide IX (Ro 31-8220) Mesylate化学構造

CAS No. 138489-18-6

サイズ 価格(税別) 在庫状況
10mM (1mL in DMSO) JPY 34800 国内在庫あり
JPY 34700 国内在庫あり
JPY 96600 国内在庫あり

代表番号: 045-509-1970|電子メール:[email protected]
よく尋ねられる質問

文献中Selleckの製品使用例(24)

製品安全説明書

現在のバッチを見る: 純度: 99.79%
99.79

Bisindolylmaleimide IX (Ro 31-8220) Mesylate関連製品

シグナル伝達経路

PKC阻害剤の選択性比較

Cell Data

Cell Lines Assay Type Concentration Incubation Time 活性情報 PMID
MCF7 Function assay 10 uM 16 hrs Inhibition of SIRT2 in human MCF7 cells assessed as tubulin hyperacetylation at 10 uM after 16 hrs by Western blot 20030343
A549 Function assay 10 uM Inhibition of SIRT2 in A549 cells assessed as ability to induce hyperacetylation of tubulin at 10 uM by Western blot analysis 17149860
HCT116 Antiproliferative assay 48 hrs Antiproliferative activity against human HCT116 cells over expressing RSK2 after 48 hrs by MTT assay, IC50=0.84μM 21488662
PC3 Cytotoxicity assay 48 hrs Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay, IC50=1.74μM 23434140
MDA-MB-231 Antiproliferative assay 48 hrs Antiproliferative activity against human MDA-MB-231 cells over expressing RSK2 after 48 hrs by MTT assay, IC50=1.77μM 21488662
MCF7 Antiproliferative assay 48 hrs Antiproliferative activity against human MCF7 cells over expressing RSK2 after 48 hrs by MTT assay, IC50=1.96μM 21488662
MCF7 Cytotoxicity assay 48 hrs Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay, IC50=1.96μM 23434140
Sf9 Function assay Inhibition of His-tagged human MSK1 expressed in Sf9 cells, IC50=0.008μM 10998351
Sf21 Function assay Inhibition of His-tagged human GSK3b expressed in Sf21 cells, IC50=0.038μM 10998351
DE3 Function assay Inhibition of human full length SIRT1 expressed in DE3 cells by fluorimetric assay, IC50=25μM 19734050
A549 Function assay Inhibition of SIRT2 in A549 cells assessed as ability to induce hyperacetylation of tubulin by Western blot analysis 17149860
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明 Bisindolylmaleimide IX (Ro 31-8220 Mesylate) is a pan-PKC inhibitor with IC50 of 5 nM, 24 nM, 14 nM, 27 nM, and 24 nM for PKC-α, PKC-βI, PKC-βII, PKC-γ, and PKC-ε, respectively, and also shows potent inhibition against MAPKAP-K1b, MSK1, GSK3β and S6K1.
Targets
PKCα [1]
(Cell-free assay)
PKCβ2 [1]
(Cell-free assay)
PKCβ1 [1]
(Cell-free assay)
PKCε [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
5 nM 14 nM 24 nM 24 nM 27 nM
In Vitro
In vitro Ro 31-8220 inhibits rat brain PKC activity with IC50 of 23 nM, and does not show any high degree of selectivity between PKC-α, PKC-β, PKC-γ, and PKC-ε. [1] Ro 31-8220 also inhibits MSK1, MAPKAPK1, RSK, GSK3β and S6K1 with a potency similar to that for PKC. In addition, Ro 31-8220 inhibits voltage-dependent Na+ channels. [2] Ro 31-8220 alters cellular protein kinase C localization and potently inhibits growth of A549 and MCF-7 cells with IC50 of 0.78 μM and 0.897 μM, respectively. [3] RO 31-8220 enhances epinephrine-induced platelet aggregation in catecholamine hypo-responsive platelets by enhancing Akt phosphorylation. [4] Ro 31-8220 significantly decreases apoE secretion from primary human macrophages by inhibiting vesicular transport of apoE to the plasma membrane without significantly affecting apoE mRNA or apoE protein levels. [5]
Kinase Assay Assay of PKC Activity
Assay mixtures contain 0.2 mg/mL peptide-gamma, 10 μM MgCl2, 0.6 mM CaCl2, 10 μM [γ-32P]ATP, 1.25 mg/mL phosphatidylserine and 1.25 ng/mL phorbol 12-myristate 13-acetate in 20 mM Hepes (pH 7.5), 2 mM EDTA, 1 mM dithiothreitol and 0.02% (w/v) Triton X-100. Peptide-γ is a synthetic peptide, GPRPLFCRKGSLRQKW, resembling the PKC-γ pseudosubstrate site, except that a serine residue replaces the pseudosubstrate alanine, converting the peptide from an inhibitor into a substrat. The assays are started by the addition of 2.5 m-units of enzyme, incubated at 30 °C for 10 min and terminated by spotting on to P81 paper, followed by extensive washing in 75 mM orthophosphoric acid. The papers are then washed in ethanol, dried, and incorporated radioactivity is determined by liquidscintillation spectroscopy.
細胞実験 細胞株 Human A549 lung and MCF-7 breast carcinoma cells
濃度 2.5 μM
反応時間 24-48 hours
実験の流れ

Human A549 lung and MCF-7 breast carcinoma cells are obtained from the European Collection of Animal Cell Cultures. Cells (passage number 10-30) are cultured in an atmosphere of 5% carbon dioxide, the former in Ham's F-12 medium with penicillin/streptomycin, the latter in minimum essential medium (Eagle's modification) with additional pyruvate (1 mM) and non-essential amino acids. Both media are supplemented with 10% FCS and glutamine (2 mM). Cells are subcultured routinely twice weekly to maintain logarithmic growth. For cell proliferation studies cells are seeded and incubated with 3 ml of medium including agents, which is replenished at intervals of 48 h (A549) or 72 h (MCF-7). Following incubation for 4 days (A549) or 6 days (MCF-7) with drugs, cell number is assessed using a Coulter Counter Model ZM. In order to achieve PKC depletion, cells are incubated for 24 h with bryostatin 1 (1 μM). Under these conditions growth inhibition caused by bryostatin 1 is negligible. Bryostatin is removed by extensive washing of the cells followed by a 2 h recovery period. In previous work using the A549 cell line this washing procedure has been shown to eliminate bryostatin-mediated effects. The cells are then incubated for a further 24 h with staurosporine, RO 31-8220, UCN-01 or H-7. In some experiments cells are incubated with inhibitor for 48 rather than 24 h, in this case bryostation was not removed and left in the incubate. After removal of agents inhibition of DNA synthesis is evaluated by measurement of [3H]Tdr incorporation into cell. Radioactivity is counted using a Packard 1500 Tricarb scintillation counter.

In Vivo
In Vivo In MLP−/− Mice, Ro 31-8220 (6 mg/kg/d, s.c.) results in a significant increase in cardiac contractility. [6]
動物実験 動物モデル MLP−/− Mice
投与量 6 mg/kg/d
投与経路 s.c.

化学情報

分子量 553.65 化学式

C25H23N5O2S.CH4O3S

CAS No. 138489-18-6 SDF Download Bisindolylmaleimide IX (Ro 31-8220) Mesylate SDFをダウンロードする
Smiles CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)CCCSC(=N)N.CS(=O)(=O)O
保管

In vitro
Batch:

DMSO : 100 mg/mL ( (180.61 mM); 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Water : Insoluble

Ethanol : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量 濃度 体積 分子量

投与溶液組成計算機(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)

mg/kg g μL

ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結果:

投与溶媒濃度: mg/ml;

DMSOストック溶液調製方法: mg 試薬を μL DMSOに溶解する(濃度 mg/mL, 注:濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法:Take μL DMSOストック溶液に μL PEG300,を加え、完全溶解後μL Tween 80,を加えて完全溶解させた後 μL ddH2O,を加え完全に溶解させます。

投与溶媒調製方法:μL DMSOストック溶液に μL Corn oil,を加え、完全溶解。

注意:1.ストック溶液に沈殿、混濁などがないことをご確認ください;
2.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください
Tags: Bisindolylmaleimide IX (Ro 31-8220) Mesylateを買う | Bisindolylmaleimide IX (Ro 31-8220) Mesylate ic50 | Bisindolylmaleimide IX (Ro 31-8220) Mesylate供給者 | Bisindolylmaleimide IX (Ro 31-8220) Mesylateを購入する | Bisindolylmaleimide IX (Ro 31-8220) Mesylate費用 | Bisindolylmaleimide IX (Ro 31-8220) Mesylate生産者 | オーダーBisindolylmaleimide IX (Ro 31-8220) Mesylate | Bisindolylmaleimide IX (Ro 31-8220) Mesylate化学構造 | Bisindolylmaleimide IX (Ro 31-8220) Mesylate分子量 | Bisindolylmaleimide IX (Ro 31-8220) Mesylate代理店